The aim of the current study was to assess the influence of anesthetic management on the effect of treatment in the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN).
The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) showed a clear benefit of intra-arterial therapy (IAT) in patients with acute ischemic stroke (AIS) caused by a proximal intracranial occlusion of the anterior circulation. 1 The intervention contrast was IAT vs no IAT against a background of best medical care including IV alteplase if indicated. The trial demonstrated a shift in the distribution of functional outcomes on the modified Rankin Scale (mRS) in favor of the intervention, which was consistent in almost all subgroup analyses. With IAT, the rate of patients being independent (mRS 0-2) increased from 19% to 33%. After publication of MR CLEAN, multiple trials confirmed the effect of IAT. [2] [3] [4] [5] Subgroup analyses in these trials will reveal new insights to further optimize selection for IAT and improve clinical outcome.
Controversy exists about the optimal anesthetic management during intra-arterial treatment. A recent consensus statement from a task force of US-based neuroanesthesiologists found the available data inconclusive. 6 Current evidence is based on the comparison of outcome after IAT in series of patients from surveys and treatment arms of randomized trials. Reported outcomes are better when IAT is performed without general anesthesia (non-GA), which means applying local anesthesia in the groin, with or without subsequent use of conscious sedation. [7] [8] [9] The non-GA approach may lead to faster treatment initiation and may avoid complications associated with intubation. Furthermore, it is known that most anesthetic agents used for GA induce sympathicolysis, which may lead to hypotension and decreased cerebral perfusion. 10, 11 On the other hand, GA reduces patient movement during the procedure and may therefore decrease procedural times and procedurerelated complications. The choice between the anesthetic approaches is most often based on the preference of the interventionist or custom of the center.
In this post hoc analysis, we investigated the influence of anesthetic management on the effect of treatment in the MR CLEAN trial. METHODS 
Methodology informing classification of evidence.
We seek to answer the following research question: Does general anesthetic management in patients with AIS caused by an intracranial occlusion of the anterior circulation modify the treatment effect of IAT found in the MR CLEAN trial? Class II level of evidence is assigned to this question.
Patients and procedures. Patient eligibility and methods of MR CLEAN have been reported previously. 1, 12 MR CLEAN was a randomized clinical trial of IAT vs no IAT in patients with a proximal arterial occlusion in the anterior circulation demonstrated on vessel imaging, treatable within 6 hours after symptom onset. The primary outcome was the score on the mRS at 90 days. Use of GA was prospectively recorded as part of the intervention Case Report Form, which was in use during the trial. Patients receiving treatment under GA were intubated, or received a laryngeal mask. Patients converted to GA during IAT were scored as non-GA according to the intention-to-treat principle. No data were collected on the use of conscious sedation, blood pressure, or cerebral blood flow during IAT. The steering committee gave no recommendations about type of anesthetic management and left this decision to the discretion of the MR CLEAN centers. Nevertheless, the majority of centers adhered to a fixed protocol regarding type of anesthetic management throughout the trial.
Outcome and safety measures. The primary outcome measure was the mRS score at 90 days. The mRS is a 7-point scale ranging from 0 (no symptoms) to 6 (dead). A score of 2 points or less indicates functional independence. 13 Secondary outcome measures included the proportion of patients who reached functional independence (mRS 0-2) at 90 days and neurologic assessment with the NIH Stroke Scale score (NIHSS; range 0-42, with higher scores indicating more severe neurologic deficits) at 24 hours and 5-7 days or discharge if earlier. Radiologic outcome measures included the modified thrombolysis in cerebral infarction (TICI) score on digital subtraction angiography (DSA), arterial recanalization measured with CT angiography or magnetic resonance angiogram at 24 hours, and final infarct volume on noncontrast CT at 5-7 days. The modified TICI score is a 4point scale, which ranges from 0 (no reperfusion) to 3 (complete antegrade reperfusion of the previously ischemic territory, with absence of visualized occlusion in all distal branches). 14 Serious adverse events included hemorrhagic complications, progression of ischemic stroke, recurrent ischemic stroke, and death. Symptomatic intracranial hemorrhage was defined as neurologic deterioration of 4 or more points on the NIHSS and intracranial hemorrhage confirmed by neuroimaging. Progression of ischemic stroke was defined as neurologic deterioration with an increase of 2 or more points on the NIHSS, follow-up CT or MRI brain compatible with diagnosis of ischemia, and no other obvious cause for neurologic deterioration. Procedure-related safety parameters included vessel perforations, dissections, and new emboli outside of the target downstream territory. 14 Statistical analysis. The primary effect parameter was the adjusted common odds ratio (acOR) for a shift in direction of a better outcome on the mRS, estimated with multivariable ordinal logistic regression analysis, which included a term for GA. This was used to estimate acORs for GA and non-GA vs control. The acOR and all secondary effect parameters were adjusted for potential imbalances in known prognostic variables adapted from the original trial protocol statistical analysis plan: age, stroke severity (NIHSS) at baseline, time since onset to randomization, previous stroke, atrial fibrillation, diabetes mellitus, and presence of intracranial carotid artery terminus occlusion. For the primary outcome, we also explored the effect of center and prerandomization mRS by additional adjustments with these variables. If patients were allocated to the intervention arm, but IAT was withheld, patients were excluded from all analyses. Furthermore, a sensitivity analysis was conducted in order to limit the potential effect of confounding by indication by excluding centers without a fixed protocol for either GA or non-GA. The direct comparison between GA and non-GA groups was conducted as secondary analyses for the primary and secondary outcome parameters.
The adjusted and unadjusted common odds ratios (ORs) were reported with 95% confidence intervals (CI) to indicate statistical precision. Binary outcomes were analyzed with logistic regression and reported as adjusted and unadjusted ORs with 95% CIs. All p values are 2-sided. Statistical analyses were performed with Stata/SE 13.1 (StataCorp, College Station, TX).
Standard protocol approvals, registrations, and patient consents. All patients or their legal representatives provided written informed consent before randomization. A central medical ethics committee and the research board of each participating center approved the study protocol. The design and data collection were performed by members of the executive committee and the local investigators of each participating center. The study sponsors were not involved in the study design, study conduct, protocol review, or manuscript preparation or review. MR CLEAN is registered under number NTR1804 in the Dutch trial register and under ISRCTN10888758 in the ISRCTN register.
RESULTS Patient and center characteristics. Patients were recruited from December 2010 until March 2014. Of the 500 patients, 233 patients (47%) were allocated to the intervention arm and 267 patients (53%) to the control arm. One patient received IAT after being allocated to the control group. Seventeen patients (7%), randomized to intervention, did not receive IAT and were excluded from the analysis. Of 216 patients, 79 patients (37%) had GA and 137 (63%) were treated in a non-GA setting (figure 1). Three of the 16 centers used GA exclusively, with an additional 4 centers demonstrating a greater than 50% usage of GA. Conversion to GA occurred in 6/137 (4.4%) of the cases because of severe movement and discomfort. Risk factors for poor outcome, clinical risk factors for stroke, and prerandomization treatment details were evenly distributed between groups (table 1).
Primary outcome. No patients were lost to follow-up. The overall effect of treatment in MR CLEAN consisted of a significant shift in direction of a better outcome in the distribution of the mRS (acOR 1.67 [95% CI 1.21-2.30]). The overall treatment effect was modified by anesthetic management (p 5 0.011). Treatment under GA was associated with a decrease of 51% (95% CI 31%-86%) of this primary effect parameter. The effect of treatment in non-GA was significant (acOR 2.18 [95% CI 1.49-3.20]). The shift in distribution between GA and control was in the same direction (acOR 1.12 [95% CI 0.71-1.78]), but the effect was smaller and not statistically significant (table 2) . The shift towards better outcome was consistent for all categories of the mRS, except for dead (figure 2). The acOR was not affected by adjustment for center ( The effect of GA, if directly compared to non-GA, resulted in a decrease of 0.58 (95% CI 0.34-0.97) for improvement on the mRS in the adjusted analyses (table e-1 on the Neurology ® Web site at Neurology. org). If converted patients were taken out of the non-GA and added to the GA group, the acOR was almost identical (0.58 [95% CI 0.35-0.97]).
Secondary outcomes and safety parameters. In this study, we found an absolute risk difference of 19% for functional independence at 3 months (mRS 0-2) in favor of the non-GA group compared to control (aOR 2.96 [95% CI 1.78-4.92]). The absolute difference in functional independence was 4% in favor of the GA group compared to control (aOR 1.17 [95% CI 0.60-2.29]). In non-GA patients, the NIHSS had improved 3.0 points more after 24 hours and 4.8 points more after 1 week than in controls. We found less infarct reduction relative to control in the GA group (12.7 mL) as compared to non-GA (21.8 mL) . No effect on improvement on the NIHSS was observed in patients treated under GA compared to controls (table 2) . The effect of GA, if directly compared to non-GA, resulted in a decrease for improvement on the mRS in the unadjusted as well as the adjusted analyses (table e-1). If a patient received treatment under GA, the average score on the NIHSS was higher after 24 hours (2.43 [95% CI 0.20-4.67]), and this difference further increased at 5-7 days or discharge (4.69 [95% CI 2.49-6.89]).
We found no major differences between groups in terms of safety outcomes, except for progressive ischemic stroke. Progression of ischemic stroke occurred more often in patients treated under GA (30% GA vs 18% control, p 5 0.017) (table 3) .
Procedural-related outcomes and safety. On average, time from door to groin puncture was 32 minutes longer in the GA group (p 5 0.001), and time from randomization to groin puncture was 16 minutes longer (p , 0.001). We found no significant differences between GA and non-GA patients in procedure duration, and time from onset to revascularization or, in case no revascularization was reached, time from onset to last angiogram (table 2) .
The rate of recanalization (modified TICI 2b/3) on posttreatment DSA was 63% in the non-GA group and 52% in the GA group, for a difference of 11% (p 5 0.19). Two vessel perforations occurred in the non-GA group; both patients died as a result. In total, 4 patients (2 in each group) had proceduralrelated dissections (table 3) . Table 1 Clinical characteristics at baseline of patients included in the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands, subdivided into intra-arterial therapy under general anesthesia (GA), intra-arterial treatment without general anesthesia (non-GA), and control arms of the trial Extent of infarct on CT as measured by NCCT ASPECTS, median (IQR) b 9 (7-10) 9 (7-10) 9 (8-10)
Intracranial arterial occlusion, c n (%) Abbreviations: A1/A2 5 anterior cerebral artery segments; ASPECTS 5 Alberta Stroke Program Early CT Score (range 0-10, higher scores indicate less early ischemic changes); ICA 5 internal carotid artery (intracranial segment); ICA-T 5 internal carotid artery with involvement of the M1 segment; IQR 5 interquartile range; M1/2 5 middle cerebral artery segments; NCCT 5 noncontrast CT; NIHSS 5 NIH Stroke Scale (range 0-42, higher scores indication more severe neurologic deficits). a Systolic blood pressure at baseline was missing in 1 patient. b ASPECTS was not available in 4 patients: NCCT was not performed in 1 patient; 3 patients had anterior cerebral artery territory strokes. c Vessel imaging was not performed in 1 patient and level of occlusion is not available. d Randomization time was missing in 2 patients. DISCUSSION In this post hoc analysis of MR CLEAN, the method of anesthesia appears to influence outcome following intra-arterial treatment. Specifically, non-GA was associated with a significant benefit of intra-arterial treatment, whereas there was no benefit of IAT in the subgroup of patients treated under GA. Our findings expand upon earlier reports, which demonstrated worse outcomes after IAT under GA. However, these studies could not examine the influence of the anesthetic approach on treatment effect because of the absence of a control group without IAT. There is currently equipoise within the treating community regarding the optimal anesthetic approach. In a recent survey of neurointerventional practitioners, 49% of respondents reported using GA primarily. 15 The results of our analysis, however, strongly challenge the use of GA as a first-line approach.
Nevertheless, there are patients who will need GA due to a decreased level of consciousness for airway protection or poor cooperation due to agitation or pain. 6 Consequently, it is important to elucidate the mechanisms by which GA negates the benefits of IAT. A recent study suggests that this detrimental effect is ultimately mediated through infarct growth. 16 The authors demonstrated that GA was an independent predictor of final infarct volume .70 cm 3 (OR 4.0, p 5 0.004). In line with this finding, we found less infarct reduction relative to control in the GA group. The unadjusted difference in volume between GA and non-GA was 15 mL (table e-1). Final infarct volumes of patients with neurologic deterioration before day 3 are not included in this analysis and might have further influenced a difference in infarct growth.
One potential mechanism by which GA may be related to infarct growth and worse outcome is the time delay associated with intubation. In MR CLEAN, the time from randomization to groin puncture was 16 minutes longer in the GA group on average. However, this did not translate to a significant difference in the time from onset to revascularization. Another potential mechanism is uncorrected anesthesia-induced blood pressure reduction and altered cerebral hemodynamics at the introduction of GA and during GA. Most anesthetic agents, for example, propofol or induction dosages of thiopental, are known to be associated with hypotension. 17 Lower mean arterial blood pressures have been associated with poorer clinical outcomes in patients treated under GA compared to conscious sedation. 11, 18 Furthermore, anesthetic agents may cause disturbance in cerebral autoregulation, potentially impairing cerebral blood flow and perfusion. 10 The effect of anesthetic agents in patients with AIS, which in itself can injure cerebral autoregulation, requires further investigation.
Another potential disadvantage of GA management is the increased risk of aspiration and at times aspiration pneumonia following intubation. 7, 19 On the other hand, emergency intubation may still be required during the non-GA approach, possibly accompanied by even a higher risk of aspiration and airway trauma. 19, 16 Because the incidence of pneumonia was equal between the groups in our study, combined with Modified Rankin Scale (mRS) score at 90 days by intention-to-treat groups
The number and percentages of patients are shown in each cell according to distribution of the mRS (range 0-6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability [able to look after own affairs without assistance but unable to carry out all previous activities], 3 a low rate (6/137) of emergency endotracheal intubations in the non-GA group, this probably does not explain poorer outcome in the GA group. In MR CLEAN, conversion to GA occurred in 4.4%, and direct availability of the anesthetic team during treatment with non-GA is recommended. Those in favor of GA have cited greater procedural safety and shorter duration of the treatment secondary to decreased patient motion. Indeed, there were 2 vessel perforations leading to death in the non-GA group, whereas no such events were noted in the GA group. However, there were no overall differences in procedure-related serious adverse events. Similarly, there was a decrease in procedure duration among GA patients, but this was not significant and did not lead to a difference in overall time to revascularization. Decrease in patient motion could potentially lead to a higher revascularization rate. On the contrary, we found an absolute difference in recanalization of 11% in favor of patients treated without GA. This may have contributed to the better outcome in the non-GA group. However, a difference in recanalization rate of this size is not sufficient enough to explain the treatment modification by GA that we observed in our study.
Our study is a post hoc analysis and may be affected by selection bias. However, there were no differences in baseline stroke severity on the NIHSS between the anesthesia groups. Moreover, 10 out of the 16 MR CLEAN centers used one approach exclusively, mitigating potential bias related to clinical patient characteristics at presentation (e.g., levels of agitations or clinical instability that are not evident from the NIHSS). In addition, the sensitivity analysis showed similar adjusted common ORs between non-GA vs control. We do not know the mechanism or cause of the treatment effect modification and therefore, it may well be so that neuroanesthesia in experienced hands leads to similar outcomes as non-GA.
Our results should be confirmed in future trials that randomize between types of anesthesia. Currently 3 trials are randomizing AIS patients between GA and conscious sedation. [20] [21] [22] Data on the type of anesthetics used during GA were not collected in MR CLEAN. Moreover, there were no data on the use of conscious sedation in the non-GA group. As previously mentioned, no systematically collected data on blood pressure or cerebral perfusion were prospectively collected during the time of anesthesia. These limitations prevent us from studying the explanatory factors and possible underlying mechanisms that might explain worse outcomes under GA. Furthermore, safety concerns might be underestimated due to sample size.
In this post hoc analysis of MR CLEAN, we found that the type of anesthetic management appears to influence outcome following IAT. Only treatment without GA was associated with a significant treatment benefit in MR CLEAN. This finding may have major implications for current interventional practice. Confirmation of these results is necessary, and randomized controlled trials are ongoing.
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